Press Room

CPHI Worldwide 2024

Start
Tuesday, October 08, 2024
End
Thursday, October 10, 2024
Location: Milan, Italy
Booth Number: 7B50 | Contract Manufacturing and Services
Hovione is present at CPHI Milan in October 2024, know more about the event and contact us to schedule a meeting

Hovione will be exhibiting at CPHI Worldwide in Milan, Italy, one of the most relevant tradeshows for the pharma industry, bringing together leading professionals from the entire pharmaceutical supply chain to network, learn and conduct vital face-to-face business.

The Specialist Integrated CDMO

Hovione can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.

We look forward to seeing you at CPHI Worldwide Milan. Meet our team and learn more about Hovione’s latest technologies and innovations in drug development and how we can support your project.

 

Find out how we can support your project.

schedule a meeting

Find more about CPHI Worldwide Milan

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026